文献速递消化系统肿瘤

分子超选择用于优化一线靶向治疗选择且不依赖原发肿瘤部位:随机FIRE-3研究在RAS野生型转移性结直肠癌中的探索性分析

Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer.
PubMed 文献 · Eur J Cancer · 2025-04-04

该研究为FIRE-3随机试验的回顾性探索性分析,纳入199例RAS/BRAF野生型且MMR proficient的转移性结直肠癌患者,用二代测序按PRESSING-3方法分为超选择组与基因改变组。超选择组接受抗EGFR治疗较贝伐珠单抗的总生存为38.5个月 vs 27.5个月(HR 0.68;95%CI 0.44-1.05;P=0.08),左右侧肿瘤均可见该趋势;基因改变组两方案总生存相当。作者认为分子超选择可能替代原发肿瘤部位用于一线靶向治疗决策。

要点

  • 超选择组抗EGFR较贝伐珠单抗总生存38.5个月 vs 27.5个月(HR 0.68;95%CI 0.44-1.05;P=0.08)。
  • 超选择获益见于右侧(HR 0.58)与左侧(HR 0.70)肿瘤。
  • 基因改变组两方案总生存相当(总队列HR 1.04;95%CI 0.61-1.79)。

核心结论

  • 作者认为,二代测序辅助的分子超选择可能替代原发肿瘤部位,成为RAS野生型转移性结直肠癌一线靶向治疗优化决策的工具。

研究设计与样本

  • 本研究为对随机FIRE-3研究的回顾性分析,该研究比较FOLFIRI联合西妥昔单抗与FOLFIRI联合贝伐珠单抗一线治疗RAS野生型患者。
  • 本分析纳入199例RAS/BRAF野生型且MMR proficient的肿瘤患者,全部患者成功完成二代测序。
  • 采用既往发表的PRESSING研究的方法,将患者分层为超选择组(无预设基因改变)或基因改变组。

主要发现

  • 按PRESSING-3超选择与抗EGFR治疗较贝伐珠单抗的总生存获益相关(38.5个月 vs 27.5个月;HR 0.68;95%CI 0.44-1.05;P=0.08)。
  • 该获益见于右侧与左侧肿瘤(HR 0.58和HR 0.70)。
  • 基因改变患者在所有亚组中总生存均劣于超选择患者。
  • 在基因改变这一不利亚组中,西妥昔单抗与贝伐珠单抗的总生存相当(总队列:HR 1.04;95%CI 0.61-1.79)。
  • 该结果不依赖原发肿瘤部位(左侧肿瘤:HR 1.10;95%CI 0.59-2.07;右侧肿瘤:HR 1.05;95%CI 0.31-3.55)。

关键数值与推荐

  • 当前指南推荐基于RAS、BRAF和DNA错配修复(MMR)状态等生物标志物分层,以在抗EGFR与抗VEGF治疗之间选择。
  • 超选择定义为无预设基因改变,基因改变组为存在预设基因改变。

临床怎么用

  • 作者认为,二代测序辅助的分子超选择可能替代原发肿瘤部位作为RAS野生型转移性结直肠癌一线靶向治疗优化选择的决策工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Molecular diagnostics play a pivotal role in guiding therapy for metastatic colorectal cancer (mCRC). Current guidelines recommend stratification based on biomarkers such as RAS, BRAF, and DNA mismatch-repair (MMR) status to select between anti-EGFR (epidermal growth factor receptor) and anti-VEGF (vascular endothelial growth factor) therapies. MATERIALS AND METHODS: This retrospective analysis evaluated the randomized FIRE-3 study that compared first-line treatment with FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab in RAS wild-type patients. The present analysis included 199 patients with RAS/BRAF wild-type MMR proficient tumors. Next-generation sequencing (NGS) was successfully performed in all patients and allowed stratification into hyperselected (no predefined genetic alterations) or gene altered subgroups using the previously published approach of the PRESSING-studies. RESULTS: Hyperselection according to PRESSING-3 was associated with a survival benefit from anti-EGFR-based therapy compared to bevacizumab (38.5 months vs. 27.5 months; HR 0.68; 95 % CI, 0.44-1.05; P = 0.08). This benefit was observed in both, right- and left-sided tumors, (HR 0.58 and HR 0.70). Patients with gene alterations showed inferior survival compared to hyperselected patients across all subgroups. In this unfavorable subgroup, application of cetuximab and bevacizumab were associated with comparable OS (total cohort: HR 1.04; 95 % CI, 0.61-1.79). Again, this finding was independent of primary tumor sidedness (left-sided tumors: HR 1.10; 95 % CI, 0.59-2.07; right-sided tumors: HR 1.05; 95 % CI, 0.31-3.55). CONCLUSION: Molecular hyperselection facilitated by next generation sequencing could replace primary tumor sidedness as a tool of decision making for optimal choice of targeted therapy in first-line treatment of RAS wild-type mCRC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Weiss L, Stintzing S, Stahler A, et al. Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer. Eur J Cancer. 2025. PMID: 40222201. doi:10.1016/j.ejca.2025.115399

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。